{"groups":[{"description":"Abemaciclib 150 milligram (mg) administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"FG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"FG001","title":"Placebo + Fulvestrant"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"9"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"5"}],"type":"On study treatment/follow up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"446"},{"groupId":"FG001","numSubjects":"223"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"441"},{"groupId":"FG001","numSubjects":"223"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"332"},{"groupId":"FG001","numSubjects":"188"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"With Overall Survival (OS) as a key outcome, participants who completed included those who died due to any cause and those who were off treatment, alive and in follow-up at the time of the final OS analysis."}